Art. -Nr.: HY-N0620

Mulberroside C

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Mulberroside C is one of the main bioactive components in white mulberry (Morus alba L.). Mulberroside C exhibits antiplatelet, antiviral and neutrophil-regulating activities, and binds to EV-A71 VP1 with a K_d value of 1.289 nM. Mulberroside C reduces the phosphorylation level of ERK, promotes the phosphorylation of IP3RI at the Ser¹⁷⁵⁶ site, and decreases calcium influx and calcium mobilization. Mulberroside C inhibits the expression of P-selectin (P-selectin). Mulberroside C upregulates the cyclic nucleotide signaling pathway in human platelets. Mulberroside C binds to IL-23R, upregulates the expression of G-CSF, GM-CSF and RASGRP1, and activates the RAS/ERK signaling pathway. Mulberroside C promotes neutrophil maturation, accelerates the recovery of leukopenia, and enhances the antibacterial activity of neutrophils. Mulberroside C inhibits the replication of hepatitis C virus in replicon cells. Mulberroside C prevents the uncoating and genome release of EV-A71, and inhibits the synthesis of viral proteins and RNA. Mulberroside C can be used in studies related to thrombosis-mediated cardiovascular diseases, chemotherapy- and radiotherapy-induced leukopenia, hepatitis C virus infection, and hand, foot and mouth disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 102841-43-0
Formel: C₂₄H₂₆O₉
Molecular Weight:458.46

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Mulberroside C Chemical Structure

CAS. Nr.: 102841-43-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[5]

EV-A71 VP1

1.289 nM (Kd)

Alle Calcium Channel Isoform-spezifische Produkte anzeigen :

Alle Ras Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

In Vitro

Mulberroside C (50-150 μM; 2 min preincubation, 5 min aggregation) dose-dependently inhibits washed human platelet aggregation induced by Collagen (HY-NP003), Thrombin (HY-114164) and U46619 (HY-108566), with an IC₅₀ of 77.3 μM against collagen-induced aggregation, and shows no cytotoxicity at the tested concentrations^[1].
Mulberroside C (50-150 μM; 3 min preincubation) reduces collagen-induced intracellular Ca²⁺ mobilization in washed human platelets in a dose-dependent manner^[1].
Mulberroside C (50-150 μM; 2 min preincubation, 5 min Collagen stimulation) regulates platelet signaling pathways in washed human platelets by upregulating the phosphorylation levels of IP₃RI and VASP, and downregulating the phosphorylation levels of ERK, cPLA₂, p38 MAPK, PI3K, Akt and PLCγ₂^[1].
Mulberroside C (50-150 μM; 0-6 min) dose-dependently inhibits collagen-induced P-selectin expression (α-granule release), serotonin and ATP release (δ-granule secretion), and thromboxane A₂ production in washed human platelets. It also suppresses collagen-induced fibrinogen binding to αIIb/β₃ in washed human platelets, and elevates intracellular cAMP and cGMP levels in human platelets^[1].
Mulberroside C (50-150 μM; 30 min preincubation, 15 min clot reaction) dose-dependently inhibits thrombin-induced fibrin clot retraction in human platelet-rich plasma^[1].
Mulberroside C directly binds to human IL-23R with a binding score of 6.36 kcal/mol^[2].
Mulberroside C (5-20 μM; 5 days) dose-dependently increases the proportion of CD11b-positive differentiated myeloid cells in NB4 and HL-60 cell lines, induces morphological differentiation of cells into mature neutrophils, and promotes the functional differentiation of NB4 cells into mature neutrophils^[2].
Mulberroside C (5-20 μM; 5 days) dose-dependently enhances the bactericidal activity of differentiated NB4 cells against *Staphylococcus aureus*^[2].
Mulberroside C (5-20 μM; 5 days) dose-dependently upregulates the expression of IL-23R, G-CSF, GM-CSF and RASGRP1 in NB4 cells, as well as the expression of IL-23R, RASGRP1, RAS, phosphorylated ERK, and myeloid transcription factors PU.1, c-Fos, CEBPA and RUNX1 in NB4 cells^[2].
Mulberroside C (3.125-400 µM; 48 h) exhibits low cytotoxicity towards RD cells (CC₅₀ = 94.82 µM) and Vero cells (CC₅₀ = 257.1 µM)^[3].
Mulberroside C (1.5625-50 µM; 48 h) potently inhibits the cytopathic effects induced by EV-A71 (BrCr strain) in RD cells (IC₅₀ = 2.09 µM) and Vero cells (IC₅₀ = 35.48 µM)^[3].
Mulberroside C (12.5-50 µM; 4 days) reduces plaque formation of EV-A71 (BrCr strain) in Vero cells in a dose-dependent manner^[3].
Mulberroside C (12.5-50 µM; 24-48 h) dose-dependently inhibits EV-A71 (BrCr strain) RNA synthesis in RD cells, and at 48 h post-infection, the 50 µM concentration reduces viral RNA levels by more than 10,000-fold^[3].
Mulberroside C (12.5-50 µM; 24 h) dose-dependently inhibits the VP1 protein expression of EV-A71 (BrCr strain) in RD cells^[3].
Mulberroside C (25 µM, administered at post-infection π -1 to 12 h, 0 to 12 h, 1 to 12 h, 3 to 12 h, 6 to 12 h, and 9 to 12 h) mainly inhibits the replication of EV-A71 (BrCr strain) at the early stage of RD cell infection, and significant antiviral activity is observed when it is added within 3 h post-infection^[3].
Mulberroside C (50 µM; mixed with virus for 1 h, followed by 1 h of cell incubation) significantly inhibits the adsorption of EV-A71 (BrCr strain) to RD cells^[3].
Mulberroside C (1.5625-50 µM; 48 h) inhibits the replication of EV-A71 (strain CC063) (IC₅₀ = 7.237 µM) and CV-A16 (strain CC045) (IC₅₀ = 15.24 µM) in RD cells^[3].
Mulberroside C (46.88-1500 µM; 30 s association, 30 s dissociation) binds to purified EV-A71 VP1 protein in a concentration-dependent manner, with a dissociation constant (K_d) of 1.289 nM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay^[2]

Cell Line:

NB4, HL-60 human myeloid leukemia cell lines
Concentration:

5, 10, 20 μM
Incubation Time:

5 days
Result:

Significantly increased the proportion of CD11b-positive cells in a dose-dependent manner: 10.0% at 5 μM, 16.1% at 10 μM, and 20.2% at 20 μM in NB4 cells, compared to 5.87% in the control group.\nDose-dependently reduced the nucleus-to-cytoplasm ratio and enhanced nuclear segmentation in cells: ~7% differentiated cells at 5 μM, ~8% at 10 μM, and ~12% at 20 μM, compared to ~2% in the control group.
Caused a significant, dose-dependent rise in the number of NBT-positive cells: ~8% at 5 μM, ~10% at 10 μM, and ~15% at 20 μM, compared to ~5% in the control group.

Real Time qPCR^[2]

Cell Line:

NB4 human myeloid leukemia cell line
Concentration:

5, 10, 20 μM
Incubation Time:

5 days
Result:

Dose-dependently upregulated the expression of genes associated with myeloid differentiation and signaling: IL-23R (2.2-fold at 5 μM, 2.5-fold at 10 μM, 3.5-fold at 20 μM), G-CSF (1.6-fold at 5 μM, 2.2-fold at 10 μM, 3.2-fold at 20 μM), GM-CSF (1.7-fold at 5 μM, 2.4-fold at 10 μM, 3.8-fold at 20 μM), and RASGRP1 (1.3-fold at 5 μM, 1.4-fold at 10 μM, 1.8-fold at 20 μM), compared to control levels.

Western Blot Analysis^[2]

Cell Line:

NB4 human myeloid leukemia cell line
Concentration:

5, 10, 20 μM
Incubation Time:

5 days
Result:

Dose-dependently upregulated the expression of key proteins involved in myeloid differentiation and signaling: IL-23R (0.75-fold at 5 μM, 0.85-fold at 10 μM, 1.1-fold at 20 μM), RASGRP1 (1.2-fold at 5 μM, 1.4-fold at 10 μM, 1.4-fold at 20 μM), RAS (1.6-fold at 5 μM, 1.9-fold at 10 μM, 1.9-fold at 20 μM), phosphorylated ERK (1.3-fold at 5 μM, 1.6-fold at 10 μM, 1.6-fold at 20 μM), PU.1 (0.5-fold at 5 μM, 0.7-fold at 10 μM, 0.7-fold at 20 μM), c-Fos (0.9-fold at 5 μM, 1.2-fold at 10 μM, 1.3-fold at 20 μM), CEBPA (1.8-fold at 5 μM, 2.8-fold at 10 μM, 2.8-fold at 20 μM), and RUNX1 (1.3-fold at 5 μM, 1.5-fold at 10 μM, 1.5-fold at 20 μM), all normalized to GAPDH or total ERK levels.

Real Time qPCR^[5]

Cell Line:

EV-A71 (BrCr strain)-infected RD cells
Concentration:

12.5, 25, 50 µM
Incubation Time:

24 h, 48 h
Result:

Dose-dependently reduced EV-A71 RNA levels at both time points.
Reduced viral RNA copy numbers by more than 10,000-fold compared to untreated controls at 48 h post-infection with 50 µM treatment.

Western Blot Analysis^[5]

Cell Line:

EV-A71 (BrCr strain)-infected RD cells
Concentration:

12.5, 25, 50 µM
Incubation Time:

24 h
Result:

Dose-dependently inhibited the expression of EV-A71 VP1 protein.
Significantly reduced the relative VP1 protein level compared to untreated infected cells, with the lowest level observed at 50 µM.

In Vivo

Mulberroside C (5-20 μM; immersion; continuous; from 3 dpf to 6 dpf) dose-dependently increases the neutrophil levels in zebrafish with irradiation- or chemotherapy-induced leukopenia and promotes the recovery from leukopenia^[2].
Mulberroside C (2-8 mg/kg, i.p.; once daily; for 11 consecutive days) dose-dependently restores white blood cell counts, promotes the proliferation and maturation of neutrophils, enhances bacterial clearance capacity, and exhibits favorable safety profiles in a mouse model of irradiation-induced leukopenia^[2].
Mulberroside C (2-8 mg/kg, i.p.; once daily for 7 consecutive days) dose-dependently promotes the recovery of peripheral blood leukocyte levels in mice with chemotherapy-induced leukopenia^[2].
Mulberroside C (25-50 mg/kg, i.p.; once daily; for 5 consecutive days) increases the survival rate of neonatal ICR mice to 30% at the dose of 50 mg/kg, reduces clinical scores, decreases viral loads in multiple tissues, and alleviates EV-A71-induced tissue damage; while the 25 mg/kg dose delays mouse death, as well as reduces viral loads and alleviates tissue damage^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Transgenic zebrafish (Tg(mpeg1: EGFP), Tg(lyz: DsRed2)) (2 days postfertilization larvae; irradiation-induced with 4 Gy X-rays at 2 dpf)^[2]
Dosage:

5 μM; 10 μM; 20 μM
Administration:

immersion; continuous; from 3 dpf to 6 dpf
Result:

Significantly increased counts of mpx:EGFP-positive neutrophils in the trunk compared to the irradiation model group, with a dose-dependent increase observed.
Significantly increased counts of lyz:DsRed2-positive neutrophils compared to the irradiation model group at 20 μM.

Animal Model:

Transgenic zebrafish (Tg(mpeg1: EGFP), Tg(lyz: DsRed2)) (2 days postfertilization larvae; chemotherapy-induced with a single 200 mg/L dose of cyclophosphamide at 2 dpf)^[2]
Dosage:

5 μM; 10 μM; 20 μM
Administration:

immersion; continuous; from 3 dpf to 6 dpf
Result:

Significantly increased counts of mpx:EGFP-positive neutrophils in the trunk compared to the cyclophosphamide model group, with a dose-dependent increase observed.
Significantly increased counts of lyz:DsRed2-positive neutrophils compared to the cyclophosphamide model group at 20 μM.

Animal Model:

Kunming (KM) mice (8 weeks old, ~25 g, equal male/female; irradiation-induced with a single 4 Gy total body X-ray dose)^[2]
Dosage:

2 mg/kg; 4 mg/kg; 8 mg/kg
Administration:

i.p.; daily; 11 days
Result:

Significantly increased peripheral white blood cell, neutrophil, monocyte, and lymphocyte counts from days 5 to 11 compared to the irradiation model group.
Significantly increased the percentage of CD11b+Ly6G+ neutrophils in peripheral blood, bone marrow, and spleen on day 9.
Significantly increased the percentage of CD34+CD117+ hematopoietic stem cells and CD117+Ly6G+ myeloid progenitor cells in bone marrow and spleen on day 9.
Significantly increased the percentage of CD3+ T cells and CD19+ B cells in peripheral blood, bone marrow, and spleen on day 9.
Induced a dose-dependent increase in Ki67+Ly6G+ proliferating immature neutrophils in bone marrow and spleen, with the 8 mg/kg group approaching normal levels.
Significantly increased bacterial clearance compared to the model group, with clearance superior to the G-CSF control group.
Caused no pathological changes in heart, liver, lungs, or kidneys at any dose.

Animal Model:

Kunming (KM) mice (8 weeks old, ~25 g, equal male/female; chemotherapy-induced with 100 mg/kg cyclophosphamide i.p. daily for 3 days)^[2]
Dosage:

2 mg/kg; 4 mg/kg; 8 mg/kg
Administration:

i.p.; daily; 7 days
Result:

Significantly increased peripheral white blood cell, neutrophil, monocyte, and lymphocyte counts from days 7 to 10 compared to the cyclophosphamide model group.
Maintained significantly higher leukocyte counts than the model group even at the lowest count on day 5.

Animal Model:

ICR mice (1-day-old, specific pathogen-free, intracerebral inoculation with EV-A71 CC063 strain)^[5]
Dosage:

25 mg/kg; 50 mg/kg
Administration:

i.p.; daily; 5 consecutive days
Result:

Improved survival rate to 30% (50 mg/kg group, vs. 0% in virus control group).
Delayed death of infected mice (25 mg/kg group).
Reduced clinical scores of infected mice compared to the virus control group (50 mg/kg group).
Significantly reduced viral loads in heart, brain, lung, intestine, and hind-limb muscle tissues compared to the virus control group (both 25 mg/kg and 50 mg/kg groups).
Prevented lung focal hemorrhages, preserved intestinal mucosa structure, and partially alleviated inflammatory cell infiltration in hind-limb muscle (50 mg/kg group).
Reduced tissue damage compared to virus control mice (25 mg/kg group).

Chemical Information

CAS. Nr. 102841-43-0
Appearance Solid
Molecular Weight 458.46
Formel C₂₄H₂₆O₉
Color White to off-white
SMILES

OC1=CC(O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)=CC(C3=CC4=C(C=C(OC(C)(C)C(O)C5)C5=C4)O3)=C1
Structure Classification
- Phenols
- Monophenols
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 62.5 mg/mL (136.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1812 mL

10.9061 mL

21.8122 mL

5 mM

0.4362 mL

2.1812 mL

4.3624 mL

10 mM

0.2181 mL

1.0906 mL

2.1812 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (296 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kwon HW, et al. In Vitro Antiplatelet Activity of Mulberroside C through the Up-Regulation of Cyclic Nucleotide Signaling Pathways and Down-Regulation of Phosphoproteins. Genes. 2021 Jun 30;12(7):1024. [Content Brief]

[2]. Zhang LW, et al. IL-23 Receptor Agonism by Mulberroside C Activates the RASGRP1/RAS/ERK Pathway Contributing to Leukopenia Treatments. Phytotherapy research : PTR. 2025 Aug;39(8):3578-3600. [Content Brief]

[3]. Cao Y, et al. Antiviral activity of Mulberroside C against enterovirus A71 in vitro and in vivo. European journal of pharmacology. 2021 Sep 05;906:174204. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1812 mL	10.9061 mL	21.8122 mL	54.5304 mL
	5 mM	0.4362 mL	2.1812 mL	4.3624 mL	10.9061 mL
	10 mM	0.2181 mL	1.0906 mL	2.1812 mL	5.4530 mL
	15 mM	0.1454 mL	0.7271 mL	1.4541 mL	3.6354 mL
	20 mM	0.1091 mL	0.5453 mL	1.0906 mL	2.7265 mL
	25 mM	0.0872 mL	0.4362 mL	0.8725 mL	2.1812 mL
	30 mM	0.0727 mL	0.3635 mL	0.7271 mL	1.8177 mL
	40 mM	0.0545 mL	0.2727 mL	0.5453 mL	1.3633 mL
	50 mM	0.0436 mL	0.2181 mL	0.4362 mL	1.0906 mL
	60 mM	0.0364 mL	0.1818 mL	0.3635 mL	0.9088 mL
	80 mM	0.0273 mL	0.1363 mL	0.2727 mL	0.6816 mL
	100 mM	0.0218 mL	0.1091 mL	0.2181 mL	0.5453 mL

Mulberroside C

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Mulberroside C

Anti-Infection Compound Library

Natural Product Library

Antiviral Compound Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Anti-Hepatitis C Virus Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Mulberroside C

Alle Calcium Channel Isoform-spezifische Produkte anzeigen

Alle Ras Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Mulberroside C

Anti-Infection Compound Library

Natural Product Library

Antiviral Compound Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Anti-Hepatitis C Virus Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Mulberroside C

Alle Calcium Channel Isoform-spezifische Produkte anzeigen

Alle Ras Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Mulberroside C Related Classifications

HY-N0620 Related Classifications